Nisha Chhabria MD, FAAN’s Post

How can we spread, scale & sustain life-saving treatments for disease? Moving #evidencebased therapies for cardiovascular-kidney-metabolic (#CKM) into action could be easier if partners come together. Read about what clinical researchers, payers, funders, journal editors, association, quality, and pharmaceutical industry leaders had to say about #knowledgetranslation at the DCRI’s #Implementation Summit. https://duke.is/imp-summit

MARKET ACCESS SURVEY: 47% of payers, IDNs, and other stakeholders plan to execute a prescription digital therapeutics strategy by 2025, according to our Second Annual Market Access Survey. - 40% say they will execute #AI plans by 2025 for administrative and manual functions, including streamlining prior authorization. “Organizations desire additional clarity regarding the value of prescription therapeutics and reimbursement,” says our colleague Tony Gibson. “CMS and FDA activity in this area will also spur payer planning in this area.” #marketaccess #pharma #biotech

🎉 Exciting News: for Diabetic patients #Evapharma Introducing Mellitofix TRIO, a groundbreaking pharmaceutical innovation designed to revolutionize healthcare. Backed by years of rigorous research and development trials, MELLITOFIX TRIO promises to redefine #diabetestreatment standards, offering hope to millions worldwide. Learn more about this transformative advancement in medicine! BY asking your physician #HealthcareInnovation #BreakthroughTreatment #evapharma #diabetes

What is needed to improve the transfer of ideas from bench to bedside, to provide more effective treatments for "patients" in need? How can stakeholders in the healthcare ecosystem—including patient groups, scientists, investors, the pharmaceutical industry and med-tech innovators—collaborate to improve and accelerate processes in the search for better outcomes, and even cures? From bench to bedside—accelerating progress in healthcare innovations | Feb 7th 2024 | https://lnkd.in/dzpTZSwm Parkinson's Europe

We’re raising awareness for #biosimilars and the important role they play in expanding access to care in healthcare systems around the globe. At Teva, we believe that unlocking value in biologics is essential, and that value creation is the key to broadening patient access and lowering system costs around the globe. Together we can make a difference in the lives of patients through policies that support #biosimilar adoption and education. Discover the magic of biosimilars here. https://lnkd.in/dBvZfHyc #biosimilars #TevaBiosimilarsUnlockingValue #Tevapharm

Clients often inquire about Medicare coverage for experimental procedures, particularly for conditions like cancer. Here’s some essential information: For unique medical conditions, clinical trials offer new, unapproved treatments. Medicare typically does not cover these experimental procedures. However, the costs are often covered by the pharmaceutical company or the entity developing the therapy. It’s crucial to stay informed and understand all your options. #Medicare #Employeebenefits #Medicarecoverage #HRInnovation #HRChallenges #HR #DoctorsChoiceusa #Healthcare

Amylyx Pharmaceuticals' ALS drug, Relyvrio, didn't meet its goals in the crucial Phase III trial, casting uncertainty on its future. Despite this, the drug's safety profile remained consistent. Considerations - 🔹 The impact on ALS treatment advancements and patient hope. 🔹 Potential regulatory discussions and the commitment to patient well-being may guide Amylyx's next steps. This setback in ALS research emphasizes the challenges in neurodegenerative disease treatment but also the unwavering quest for solutions. #ALS #HealthcareNews #ClinicalTrials

The Inflation Reduction Act will increase drug affordability—but that money comes from somewhere. Ryan Cox, VP, Director, PRECISIONvalue Access Experience Team, discusses the unintended consequences for payers, biopharmaceuticals—and the future of patient’s drug choices. View now. #pharmamarketing #marketaccess #inflationreductionact #Access90 #biopharmaceuticals

Why Behavioral Science Is Needed On Day One To Support Patient-Focused Drug Development - https://lnkd.in/eVvre-mn - By William Hind and Lisa Campbell Pharma companies can enhance patient-centricity by using behavioral science to understand patient needs beyond quality, safety, and efficacy. This approach informs drug design and delivery, aligning with FDA guidance and improving the success of new therapies, especially for rare diseases.

NEW THIS WEEK! The 2024 U.S. Generic & Biosimilar Medicines Savings Report Since the first #biosimilar launch in 2015, patients and the U.S. healthcare system have saved around $36 billion. Although savings have grown, biosimilar adoption remains too low! Learn about how PBM formulary practices favoring high-priced brand biologics with high rebates prevent patient access to lower-cost biosimilars: https://lnkd.in/emdKKqjY #GRxBiosimsSavingsReport  Association for Accessible Medicines